<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819999</url>
  </required_header>
  <id_info>
    <org_study_id>SCRX001-004</org_study_id>
    <nct_id>NCT02819999</nct_id>
  </id_info>
  <brief_title>A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stemcentrx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stemcentrx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the effect of rovalpituzumab tesirine in the frontline
      treatment of small cell lung cancer (SCLC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLT) of rovalpituzumab tesirine when administered as monotherapy, in series or in combination with frontline chemotherapy to subjects with delta-like protein 3 (DLL3)-expressing extensive-stage small cell lung cancer (SCLC)</measure>
    <time_frame>within 21 days after first dose of rovalpituzumab tesirine</time_frame>
    <description>For Phase 1a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment emergent adverse events (TEAEs)</measure>
    <time_frame>through 30 days after last dose of study treatment</time_frame>
    <description>For Phase 1a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of subjects with CTCAE Grade &gt;2 laboratory abnormalities</measure>
    <time_frame>through 30 days after last dose of study treatment</time_frame>
    <description>For Phase 1a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>4 years</time_frame>
    <description>For Phase 1b</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies (ATAs) against rovalpituzumab tesirine</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Phase 1a)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Cmax (Maximum plasma concentration observed )</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: AUC0-tau (Area under the plasma concentration-time curve within a dosing interval)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: AUC0-∞ (Area under the curve from time 0 extrapolated to infinity)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Tmax (Time of Cmax)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Ctrough (Observed plasma concentrations at trough)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: T1/2 (Terminal half-life)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: CL (Clearance)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Vss (Volume of distribution at steady state)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs</measure>
    <time_frame>4 years</time_frame>
    <description>For Phase 1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs (Heart Rate)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs (Blood pressure)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs (Temperature)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs (Weight)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs (Respirations)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) score</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Rovalpituzumab Tesirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rovalpituzumab Tesirine 0.3 mg/kg IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rovalpituzumab Tesirine followed by Cisplatin, Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rovalpituzumab Tesirine 0.3 mg/kg IV infusion followed by Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rovalpituzumab Tesirine with Cisplatin, Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion and Rovalpituzumab Tesirine 0.1 mg/kg IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rovalpituzumab Tesirine following Cisplatin, Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion followed by Rovalpituzumab Tesirine 0.3 mg/kg IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rovalpituzumab Tesirine</intervention_name>
    <description>Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).</description>
    <arm_group_label>Rovalpituzumab Tesirine</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine followed by Cisplatin, Etoposide</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine with Cisplatin, Etoposide</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine following Cisplatin, Etoposide</arm_group_label>
    <other_name>SC16LD6.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Rovalpituzumab Tesirine followed by Cisplatin, Etoposide</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine with Cisplatin, Etoposide</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine following Cisplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>Rovalpituzumab Tesirine followed by Cisplatin, Etoposide</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine with Cisplatin, Etoposide</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine following Cisplatin, Etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years with histologically- or cytologically-confirmed, extensive-stage,
             chemotherapy-naïve SCLC

          -  DLL3-expressing SCLC based on central immunohistochemistry (IHC) assessment. Positive
             is defined as staining in ≥75% of tumor cells.

          -  Eastern Cooperative Oncology Group performance status of 0 or 1.

          -  Minimum life expectancy of at least 12 weeks.

          -  Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior
             to initiation of study drug.

          -  Satisfactory laboratory parameters within defined parameters (ANC, platelet count, Hb,
             total bilirubin, ALT, AST and GFR)

          -  Subjects with a history of CNS metastases must have completed definitive treatment
             prior to first dose of study treatment, off or on a stable dose of corticosteroids

          -  Use of effective contraception method during and for 1 year following study drug
             dosing if female of childbearing potential or sexually active male

        Exclusion Criteria:

          -  Prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors,
             other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, T-cell
             or other cell-based or biologic therapies, or any other anticancer therapy for the
             treatment of (limited or extensive) SCLC.

          -  Any significant medical condition, that, in the opinion of the investigator or
             sponsor, may place the subject at undue risk from the study.

          -  Documented history of a cerebral vascular, unstable angina, myocardial infarction, or
             cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV within
             6 months prior to their first dose of study drug.

          -  Recent or ongoing serious infection.

          -  Women who are pregnant or breastfeeding.

          -  History of another invasive malignancy that has not been in remission for at least 3
             years. Exceptions: nonmelanoma skin cancer, curatively treated localized prostate
             cancer, and cervical cancer in situ on biopsy or squamous intraepithelial lesion on
             PAP smear.

          -  Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, or known hypersensitivity
             to rovalpituzumab tesirine or excipient contained in the drug formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sreeni Yalamanchili, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Stemcentrx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SCRX001-004 Study Team</last_name>
    <email>SCRX001-004@stemcentrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Camidge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Jotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tarek Mekhail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Hann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Morganzstern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Ward, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Afshin Dowlati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathan Pennell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Burns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Richey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-381-2637</phone>
    </contact>
    <investigator>
      <last_name>Sridhar Beeram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

